Alnylam

Ex-Sanofi chief Olivier Brandicourt, current Blackstone advisor, jumps on Alnylam board
Endpoints
Fri, 02/28/20 - 10:44 am
Sanofi
Olivier Brandicourt
Alnylam
With Rising Drug Prices a Concern, Some Companies Enact Their Own Control Plans
BioSpace
Wed, 01/15/20 - 10:59 am
drug pricing
Roche
Eli Lilly
Amgen
Alnylam
Sanofi
JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval
Fierce Pharma
Tue, 01/14/20 - 10:44 am
Alnylam
RNAi
Givlaari
John Maraganore
JPMHC 2020
3 Rare Disease Drug Launches to Watch in 2020
Motley Fool
Sat, 01/4/20 - 07:38 pm
Global Blood Therapeutics
sickle cell disease
Oxbryta
Novartis
SCD
Adakveo
Alnylam
Givlaari
acute hepatic porphyria
FDA
With trial win, Alnylam to seek approval for first treatment of rare kidney disease
Biopharma Dive
Tue, 12/17/19 - 10:29 am
Alnylam
lumasiran
clincial trials
RNAi
kidney disease
Primary Hyperoxaluria
5 New Drug Approvals the FDA Gave Top Priority
Motley Fool
Sat, 11/30/19 - 11:22 pm
FDA
drug approvals
Global Blood Therapeutics
Oxbryta
Alnylam
Givlaari
BeiGene
Brukinsa
Vertex Pharmaceuticals
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
RAPS.org
Wed, 11/27/19 - 12:39 pm
FDA
Vertex Pharmaceuticals
Trikafta
Novartis
Adakveo
Alnylam
Givlaari
BeiGene
Brukinsa
Global Blood Therapeutics
Oxbryta
drug approvals
Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class
Motley Fool
Sat, 11/23/19 - 04:05 pm
RNAi
Givlaari
Alnylam
FDA's rapid review pace nets an early approval for Alnylam's second drug
Biopharma Dive
Wed, 11/20/19 - 10:51 pm
FDA
Alnylam
Givlaari
givosiran
RNAi
porphyria
The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
Yahoo/Benzinga
Sun, 11/17/19 - 08:47 pm
AHA
The Medicines Company
Intrexon
Alnylam
Pieris
Roche
These Biotechs Were Focused on One Line on Pfizer’s Earnings Report
Motley Fool
Thu, 10/31/19 - 11:51 pm
Pfizer
Vyndaqel
Alnylam
Akcea Therapeutics
Ionis Pharmaceuticals
Eidos Therapeutics
Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
EP Vantage
Sat, 10/19/19 - 01:36 pm
Novartis
fevipiprant
severe asthma
Alnylam
lumasiran
Primary Hyperoxaluria
Pfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst
Fierce Pharma
Fri, 10/18/19 - 07:45 pm
Pfizer
tafamidis
FDA
Vyndaqel
Alnylam
Ionis
ATTR amyloidosis
Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn
Fierce Pharma
Tue, 07/9/19 - 06:32 pm
Ionis
Tegsedi
RNAi
Alnylam
Onpattro
NICE
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
Xconomy
Mon, 05/20/19 - 09:41 am
The Medicines Company
Alnylam
inclisiran
Can Pfizer Leap Over the Competition With This Potential Blockbuster?
Motley Fool
Wed, 05/8/19 - 10:03 am
Pfizer
Vyndamax
tafamidis
ATTR
Alnylam
Onpattro
Akcea Therapeutics
Tegsedi
Eidos Therapeutics
AG10
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
Xconomy
Mon, 05/6/19 - 10:54 am
FDA
Pfizer
tafamidis
Vyndaqel
Vyndamax
ATTR
Alnylam
Akcea
Vendu! Weeks after Sanofi cuts ties to Alnylam, the pharma giant offloads $842M of its stock
Endpoints
Fri, 05/3/19 - 10:52 pm
Sanofi
Alnylam
Alnylam posts strong Onpattro sales as competition heats up
Biopharma Dive
Thu, 05/2/19 - 08:12 pm
Alnylam
Onpattro
earnings
Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More
Xconomy
Sun, 04/21/19 - 12:16 am
FDA
CRISPR
gene therapy
Achaogen
Allergan
Alnylam
Adverum Biotechnologies
Blackstone Life Sciences

Pages